Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tepotinib + Paclitaxel in MET-Altered Advanced Gastric/GEJ Cancer
NCT05439993Phase 2Recruiting
- Sponsor
- Hallym University Medical Center
- Start
- Mar 2022
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tepotinib in gastric cancer (GC), gastroesophageal junction cancer, sponsored by Hallym University Medical Center. Started Mar 2022; status: recruiting.
02
Drugs
tepotinib
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT05439993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05439993.